Compare MIRM & EMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | EMN |
|---|---|---|
| Founded | 2018 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.3B |
| IPO Year | 2019 | 1996 |
| Metric | MIRM | EMN |
|---|---|---|
| Price | $89.69 | $66.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $119.85 | $79.31 |
| AVG Volume (30 Days) | 504.0K | ★ 945.6K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.77% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 2.51 |
| Revenue | $19,138,000.00 | ★ $8,752,000,000.00 |
| Revenue This Year | $26.22 | $3.06 |
| Revenue Next Year | $22.04 | $3.47 |
| P/E Ratio | ★ N/A | $26.37 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $63.23 | $56.11 |
| 52 Week High | $130.00 | $83.47 |
| Indicator | MIRM | EMN |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 42.91 |
| Support Level | $88.08 | $65.72 |
| Resistance Level | $98.03 | $70.42 |
| Average True Range (ATR) | 3.98 | 1.41 |
| MACD | -0.60 | -0.06 |
| Stochastic Oscillator | 14.55 | 35.43 |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.